Merck’s Keytruda Works With Lenvima In Renal Cancer, But Not With Yervoy In Lung Cancer

Merck’s PD-1 inhibitor combined with Lenvima offered benefit in RCC, but use with Bristol’s Yervoy in metastatic NSCLC showed no benefit compared to Keytruda monotherapy.